DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Seckel syndrome 9 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSeckel syndrome 9 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for seckel syndrome 9 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
The 1982 review of the literature found that of roughly 60 patients published as having Seckel syndrome, only one third met the diagnostic criteria originally proposed by Seckel, suggesting the condition is a heterogeneous group of microcephalic primordial dwarfisms rather than a single entity. A 2017 case report of a nine-year-old child describes the classic features as proportionate dwarfism of prenatal onset, severe microcephaly with a bird-headed appearance (beaked nose, receding forehead, prominent eyes, micrognathia), and mental retardation, with additional abnormalities possible in the cardiovascular, hematopoietic, endocrine, gastrointestinal, and central nervous systems, and notes that psychomotor development is usually poor. A 2016 overview states that Seckel syndrome belongs to the family of Microcephalic Primordial Dwarfisms and that the genetic defects identified so far highlight a requirement for optimal cell cycle control and DNA replication for normal human development.
A 2023 case report of a consanguineous Pakistani family with two siblings describes severe microcephaly, severe intellectual disability, short stature, absence of speech, pointed nose, narrow face, and bilateral cataract. Whole-exome sequencing identified a novel bi-allelic missense variant in the RTTN gene (NM_173630.4: c.57G>T, p.Glu19Asp) that co-segregated with the phenotype. The report states that 40 cases of Seckel syndrome had been reported in the literature due to mutations in the ATR, TRAIP, RBBP8, NSMCE2, NIN, CENPJ, DNA2, CEP152, and CEP63 genes, and that this RTTN variant expands the genetic knowledge and phenotype spectrum in the Pakistani population.
A 2014 case report describes a six-year-old boy with Seckel syndrome and aplastic anaemia who underwent allogeneic bone marrow transplantation from a ten-of-ten HLA matched unrelated donor. The patient was reported to be in good health with no further complications at day 771 post-transplant. The authors conclude that bone marrow transplantation is an acceptable therapeutic option for Seckel syndrome complicated by haematological alterations.
What is still missing is any systematic trial of a drug therapy for the core growth and neurodevelopmental features of Seckel syndrome. The only interventional report is a single successful stem cell transplant for a secondary haematological complication. No drug has been tested in a controlled fashion for the syndrome itself, and no molecular therapy targeting the underlying DNA replication or cell cycle defects has reached human studies. Patient stratification by specific gene mutation is not yet standard, and funding for natural history studies or preclinical drug screening in this ultra-rare condition remains absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Medical Genetics · 1982 · 202 citations
Studies of microcephalic primordial dwarfism I: Approach to a delineation of the seckel syndrome
AbstractAbstract The literature dealing with the Seckel syndrome is discussed critically. Some 60 patients have been published as having the Seckel syndrome. The diagnostic criteria proposed by Seckel are met by only 1/3 of these. It seems evident that this “syndrome” is a heterogeneous group of microcephalic primordial dwarfism. An approach to the delineation of the Seckel syndrome is given.
Microcephaly, Short Stature, Intellectual Disability, Speech Absence and Cataract Are Associated with Novel Bi-Allelic Missense Variant in RTTN Gene: A Seckel Syndrome Case Report
AbstractThe RTTN gene encodes centriole biogenesis, replication, symmetry and cohesion, basal body organization and has recently been associated with the appearance of microcephaly syndromes. RTTN-related neurological defects including microcephaly, intellectual disability, congenital dwarfism, ophthalmic manifestations, and epilepsy are mainly due to abnormal brain development pathways and loss-of-function protein mutations. We present a consanguineous Pakistani family clinically suspected of Seckel syndrome with severe microcephaly, severe intellectual disability, short stature, absence of speech, pointed nose, narrow face and bilateral cataract in two siblings residing in the suburbs of Islamabad. Forty cases of Seckel syndrome have been reported to date in the literature due to mutations in the ATR, TRAIP, RBBP8, NSMCE2, NIN, CENPJ, DNA2, CEP152 and CEP63 genes. The objective of the study was to perform a clinical diagnosis, genetic analysis, and pathophysiology of Seckel syndrome in the proband. Whole-exome sequencing discovered NM_173630.4: c.57G > T(pGlu19Asp) missense variant in exon 2 of the RTTN gene that co-segregates in the family. This novel variant, to the best of our knowledge, is pathogenic and with autosomal recessive inheritance expressed as Seckel syndrome in the affected members of the family. The present study has expanded the genetic knowledge of novel RTTN gene variants associated with Seckel syndrome and has broadened its phenotype spectrum in the Pakistani population, which comprises diverse ethnicities. We hope that our study will open new horizons for individual molecular diagnosis and therapeutics to improve the life of patients with this congenital syndrome.
Successful outcome of allogeneic stem cell transplantation in Seckel syndrome
AbstractSeckel syndrome is a rare autosomal recessive disease, genetically heterogeneous, characterized by short stature, prenatal microcephaly, intellectual disability, dysmorphic features, chromosomal instability, and hematological disorders. We report the case of a six-yr-old boy with Seckel syndrome and aplastic anemia who underwent successful allogeneic bone marrow transplantation from ten of ten HLA matched unrelated donor. Currently the patient is on D+771, in good health conditions and with no further complications. In conclusion, this case indicates that bone marrow transplantation is an acceptable therapeutic option for Seckel syndrome complicated by hematological alterations.
International Journal of Health Sciences and Pharmacy · 2017 · 1 citations · open access
Seckel Syndrome in a 9 Year Old Child
AbstractSeckel Syndrome first defined by Seckel in 1959, is a rare (incidence 1:10000) genetically heterogeneous, autosomal recessive disorder presenting at birth. This syndrome is characterised by a proportionate dwarfism of prenatal onset, severe microcephaly with a bird headed appearance (beaked nose, receding forehead, prominent eyes and micrognathia) and mental retardation in addition to the characteristics craniofacial dysmorphism and skeletal defects, abnormalities have been described in the cardiovascular hematopoietic, endocrine, gastrointestinal and central nervous system. Usually such patients have poor psychomotor development.
Oxford University Press eBooks · 2016 · 0 citations
Seckel Syndrome
AbstractSeckel syndrome belongs to the family of Microcephalic Primordial Dwarfisms (MPDs), a clinically heterogeneous group of conditions associated with growth retardation, microcephaly, characteristic skeletal features and additional abnormalities. Over the last decade or so the underlying genetic defects for some MPDs have started to emerge. So far, these defects collectively highlight the requirement for optimal cell cycle control and progression including DNA replication for normal human development. In this chapter I will overview the genes implicated in Seckel syndrome. I will detail the clinical presentation of this disorder; contrasting it to the other overlapping MPDs, and describe current models underlying the molecular pathogenesis of the associated genetic defects, highlighting their inter-related and associated biological impacts. But first, I will provide some background to illuminate the precise origin of Seckel syndrome. My intention here is to place its origin or more precisely, its evolution, into some context, with the aim of helping to explain why this condition has often been mis- and/or over-diagnosed.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
